BiotechTube

Bezlotoxumab Injection [Zinplava]

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection

Conditions

Clostridium Difficile Infection

Trial Timeline

Oct 1, 2019 → Oct 28, 2022

NCT ID
NCT04075422

About Bezlotoxumab Injection [Zinplava]

Bezlotoxumab Injection [Zinplava] is a pre-clinical stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04075422. Target conditions include Clostridium Difficile Infection.

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile Infection were approved

Approved (9) Terminated (5) Active (11)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
✅Vancomycin + FidaxomicinMerckApproved
✅bezlotoxumab + Vancomycin OralMerckApproved
✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved
✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04075422Pre-clinicalCompleted

Competing Products

20 competing products in Clostridium Difficile Infection

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
PAR-101/OPT-80 + VancomycinMerckPhase 3
40